**Paper:** [The political polarization of health outcomes in the USA](https://doi.org/10.1038/s41562-026-02474-9)

**Authors:** Elizabeth Elder, Neil A. O'Brian

**Journal:** Nature Human Behaviour, 2026

**Why it matters:** Political ideology has emerged as a measurable social determinant of health in the United States, with conservative Americans showing widening gaps in both clinical biomarkers and mortality that persist after accounting for COVID-19, geography, and demographic change.

---

**Summary**

To move beyond the well-known limitations of county-level ecological data and subjective self-reports, Elder and O'Brian used individual-level longitudinal data from the Add Health cohort — the same participants tracked from adolescence in 1994 through adulthood — alongside CDC death records. They focused on Waves 4 and 5 of the survey (2008–2009 and 2016–2018), during which trained interviewers collected five objective clinical biomarkers in respondents' homes: BMI, lipid panels, HbA1c (a blood glucose marker), blood pressure, and C-reactive protein (a marker of systemic inflammation). These were combined into a single comorbidity index. In Wave 4, when participants were in their late 20s to early 30s, equivalence testing revealed no statistically significant health gap across the political spectrum. By Wave 5, the most conservative respondents had diverged significantly, with the gap representing roughly one-third of a standard deviation on the comorbidity index — an unusually large split for a relatively young cohort over less than a decade.

To decompose the gap's origins, the authors applied a Kitagawa-Oaxaca-Blinder decomposition, which partitions a between-group difference into changes in observable characteristics versus unexplained factors. Approximately half of the widening was explained by socioeconomic sorting: individuals with higher education and income — strongly protective health endowments — increasingly aligned with the liberal coalition, while less healthy individuals shifted toward the conservative camp. Conservatives showed relative gains in marriage rates and religious community ties, both protective factors, but these were outweighed by the income and education effects.

The remaining unexplained gap persisted into the mortality data: cross-referencing the cohort with the National Death Index through 2020–2022, very conservative respondents were 1.144 percentage points more likely to die of internal causes than very liberal respondents. Critically, this gap held after excluding COVID-19 deaths and after applying county fixed effects — meaning the disparity survived among liberals and conservatives living in the same local health jurisdiction. A large 2024 public opinion survey (the CHIP 50, n > 21,000) pointed toward a behavioral mechanism: right-leaning individuals reported substantially lower trust in primary care providers and emergency physicians, lower willingness to seek care for acute symptoms, and — among those with chronic conditions like hypertension or diabetes — greater skepticism about the safety and effectiveness of their own medications.

---

**Three takeaways**

1. A comorbidity gap between conservative and liberal Americans was essentially absent in 2008–2009 but had grown to roughly one-third of a standard deviation by 2016–2018; Kitagawa-Oaxaca-Blinder decomposition attributes approximately half of this widening to socioeconomic sorting into political coalitions.

2. By the early 2020s, very conservative respondents faced a statistically significant elevation in non-COVID internal-cause mortality (heart disease, cancer, stroke) that was not explained by geographic location, local public health policy, demographic composition, or the COVID-19 pandemic.

3. Survey data from 2024 show that right-leaning individuals — measured by vote choice, partisanship, and ideological self-placement — are significantly less likely to seek care for acute cardiac symptoms and more likely to doubt the effectiveness of medications they are already taking for chronic conditions, suggesting declining medical trust as a partial behavioral driver of the mortality gap.

---

**Read the paper:** [https://doi.org/10.1038/s41562-026-02474-9](https://doi.org/10.1038/s41562-026-02474-9)

**Paper:** [Enable CAR T cell immunotherapy in glioblastoma by modifying its microenvironment via oncolytic adenovirus encoding bispecific T cell engager](https://doi.org/10.1016/j.omton.2026.201201)

**Authors:** Moon Jung Choi, Eui Young So, Bedia Akosman, Young Eun Lee, et al.

**Journal:** Molecular Therapy Oncology, 2026

**Why it matters:** Glioblastoma has resisted every modern immunotherapy due to its physical and immunological defenses, and this study presents a multimodal platform that simultaneously addresses immune exclusion, antigen escape, and tumor heterogeneity.

---

**Summary**

Glioblastoma (GBM) remains one of the most treatment-resistant cancers, with median survival stubbornly anchored near 12–18 months despite maximal surgical resection, radiation, and temozolomide chemotherapy. CAR T cell therapies have shown only transient responses in clinical trials, stymied by two compounding problems: the blood-brain barrier (BBB) physically restricts immune cell trafficking into the tumor, and GBM's extreme antigen heterogeneity allows surviving cells to simply downregulate the targeted antigen and escape. To address this, the authors engineered a conditionally replicative oncolytic adenovirus — Ad5-Δ24-RGD, which carries a 24-base-pair deletion in its E1A gene preventing replication in cells with intact retinoblastoma (RB) tumor suppressor pathway — to act as a local factory, continuously producing a bispecific T cell engager (BiTE) that simultaneously binds CD3 on T cells and IL-13Rα2, an antigen highly specific to GBM. This "OV-BiTE" was then combined with intravenously infused CAR T cells dual-targeted to EGFR and EGFRvIII, creating a three-antigen crossfire against the tumor.

In 3D GBM-BBB spheroid models incorporating astrocytes, endothelial cells, and pericytes, OV-BiTE treatment downregulated key endothelial tight junction proteins — Claudin-5, Occludin, and ZO-1 — measurably increasing barrier permeability and T cell infiltration compared to virus or controls alone. In a subcutaneous U87 GBM xenograft mouse model, sequential intratumoral OV-BiTE injection followed three days later by intravenous dual-targeted CAR T cell infusion produced markedly superior tumor regression versus any monotherapy arm, with histology confirming deep CD3+ T cell infiltration into the tumor core and significant reduction in IL-13Rα2-expressing cells. Importantly, mice tolerated the combination without body weight loss or overt toxicity signs. The critical caveat is that all in vivo efficacy data derives from a subcutaneous flank model rather than an intracranial orthotopic model, meaning true BBB dynamics, neuroinflammatory risk, and cerebral edema potential remain untested in a physiologically relevant CNS setting.

---

**Three takeaways**

1. OV-BiTE infection actively downregulated endothelial tight junction proteins Claudin-5, Occludin, and ZO-1 in GBM-BBB spheroid models, significantly increasing the physical infiltration of circulating T cells across the barrier compared to untreated or virus-only controls.

2. Sequential intratumoral OV-BiTE followed by systemic dual-targeted EGFR/EGFRvIII CAR T cell infusion produced superior tumor regression and deeper intratumoral CD3+ T cell infiltration in a xenograft mouse model compared to either CAR T cell therapy or oncolytic virus alone.

3. Simultaneously targeting three distinct antigens — IL-13Rα2 via the virus-encoded BiTE, and EGFR/EGFRvIII via the CAR T cells — produced a multi-antigen crossfire that directly countered GBM's antigen escape mechanism, which monotherapy approaches consistently fail to overcome.

---

**Read the paper:** [https://doi.org/10.1016/j.omton.2026.201201](https://doi.org/10.1016/j.omton.2026.201201)

**Paper:** [Climate-driven depopulation and adaptation realities in America's coastal ground zero](https://doi.org/10.1038/s41893-026-01820-z)

**Authors:** Torbjörn E. Törnqvist, Brianna Castro, Jesse M. Keenan, Jayur M. Mehta, Zhixiong Shen

**Journal:** Nature Sustainability, 2026

**Why it matters:** The central U.S. Gulf Coast — identified by the IPCC as the single most exposed low-elevation coastal zone globally this century — offers an empirical test case for how geology, archaeology, and demographics together constrain what climate adaptation can realistically achieve.

**Summary**

The paper asks a deceptively simple question: given what the physical record actually tells us about past sea levels, what is genuinely possible for coastal Louisiana going forward? The authors anchor their analysis in field evidence from the last interglacial period (LIG, ~125,000 years ago), when global temperatures were roughly 0.5–1.5 °C above pre-industrial values — a threshold modern warming is already approaching. They located the LIG shoreline at the Ponchitula Ridge, roughly 50 km north of present-day New Orleans. After correcting for tectonic subsidence driven by the Baton Rouge fault zone, the authors calculate that relative sea level (RSL) during the LIG stood at approximately +7.5 meters — implying a committed future RSL rise of 3–7 meters and a shoreline that could migrate up to 100 km inland. That geological baseline, they argue, makes long-term static coastal defense physically impossible, regardless of engineering ambition.

The paper then layers in archaeological evidence showing that Native American communities in the delta successfully navigated this same geological instability through adaptive mobility — tracking deltaic lobe switching (avulsion), constructing elevated shell-midden platforms on natural levees, and migrating when landscapes degraded past a threshold. Modern land-tenure systems, fixed mortgages, and rigid zoning have replaced that mobility with what the authors call a "socio-ecological trap," in which adaptation measures like home elevation paradoxically deepen financial and psychological commitment to doomed coordinates. Present-day demographic data support this framing: the region is already experiencing a chaotic "pulse-retreat" pattern of outmigration, with Orleans Parish losing ~25% of its population since 2000 and rural Cameron Parish losing more than half, declines punctuated sharply by hurricanes Katrina, Rita, Laura, and Delta.

The paper's most pointed policy argument concerns Louisiana's 2025 cancellation of two major sediment diversion projects — the only scientifically supported mechanism for large-scale, sustainable land building. The authors contend this decision eliminates the primary tool for buying time and forecloses the possibility of orderly, multi-generational managed relocation to higher Pleistocene terraces north of Lake Pontchartrain. A key limitation the authors acknowledge is that the exact timeline for committed sea-level rise remains uncertain; the geological evidence establishes physical capacity, not a precise delivery date.

**Three takeaways**

1. Field evidence from the LIG shoreline, corrected for regional subsidence, places past RSL at +7.5 meters — committing the central Gulf Coast to 3–7 meters of future relative sea-level rise and potential shoreline retreat of up to 100 km inland.

2. Present-day outmigration follows a pulse-retreat pattern in which hurricane shocks trigger sharp, partially irreversible population drops; socioeconomic stressors — particularly collapsing property insurance markets — amplify environmental stress into financial displacement, distinguishing Louisiana's trajectory from Florida's continued coastal growth.

3. Louisiana's cancellation of large-scale sediment diversions in favor of organic marsh creation removes the only biophysically viable method of sustained land building, drastically compressing the window available for coordinated managed relocation and making chaotic, market-driven displacement the default outcome.

**Read the paper:** [https://doi.org/10.1038/s41893-026-01820-z](https://doi.org/10.1038/s41893-026-01820-z)

**Monday Immune Engager** — our weekly pick from the latest immune-engager digest.

**Paper:** [Engineering of acidic pH-responsive anti-CD3 binding antibodies](https://doi.org/10.1080/19420862.2026.2658902)

**Authors:** Grégory La Sala, Katharina B. Kroell, Mudita Pincha, Christian Gassner, et al.

**Journal:** mAbs, 2026

**Why it matters:** Tumor-selective T-cell engagers could dramatically reduce the on-target, off-tumor toxicity that limits current CD3-directed cancer immunotherapies.

**Summary**

T-cell engagers are bispecific antibodies that physically tether a cytotoxic T-cell to a tumor cell by simultaneously binding a tumor-associated antigen and the CD3 receptor complex — the master activation switch of T-cells. The problem is that CD3-binding potency is indiscriminate: if the target antigen appears even at trace levels on healthy tissue, activated T-cells will attack it. This paper from Roche exploits a well-characterized feature of the tumor microenvironment — a local pH of roughly 6.5–6.8 driven by lactic acid accumulation and poor vascular clearance, versus the tightly regulated systemic pH of 7.4 — to engineer anti-CD3 antibodies that bind avidly inside a tumor but disengage in healthy tissue.

Starting from the parental antibody 40G5C, the team built a phage-display library of hundreds of trillions of sequence variants, selectively incorporating pH-sensitive amino acids (histidine, aspartate, glutamate) at solvent-exposed positions and the CD3 interface. Only 1–2% of recovered clones showed genuine pH-responsive behavior, and the dominant hits were unexpected: threonine-to-aspartate (T89LD) and glutamine-to-glutamate (Q90LE) substitutions in the CDRL3 loop — neither of which directly contacts the CD3 antigen. Constant-pH molecular dynamics (CpHMD) simulations revealed two distinct allosteric mechanisms: Q90LE causes electrostatic rigidification of the CDR binding loops at acidic pH, collapsing into a floppy, non-binding conformation at pH 7.4; T89LD shifts the angle between the variable heavy and light chain domains by approximately 2 degrees at neutral pH, distorting the binding pocket enough to prevent CD3 engagement.

Functional assays in primary human PBMCs confirmed a 789-fold difference in binding affinity between pH 6.5 and pH 7.4 for the Q90LE variant, with corresponding selective T-cell activation (measured by CD69 upregulation). The engineered switch came at a cost to raw potency, but combining Q90LE with affinity-enhancing histidine mutations in the variable domains produced an optimized clone — P1AK5F7-19 — that restored parental-level potency at acidic pH while retaining the safety window at physiological pH.

**Three takeaways**

1. pH-dependent CD3 binding can be achieved through allosteric mutations in the CDRL3 loop that do not contact the antigen directly, challenging the field's conventional focus on mutating residues at the binding interface.

2. CpHMD simulations identified two mechanistically distinct pH switches: loop rigidification (Q90LE) and a ~2-degree VH/VL domain tilt (T89LD), either of which is sufficient to ablate binding at neutral pH.

3. The potency-selectivity trade-off inherent to pH-switch engineering was resolved by combining the Q90LE safety-switch mutation with histidine-based affinity-enhancing mutations, yielding a clone that matched parental T-cell activation at pH 6.5 while remaining largely inactive at pH 7.4 in human primary cell models.

**Read the paper:** https://doi.org/10.1080/19420862.2026.2658902

**Paper:** [Impact of high-power short-duration atrial fibrillation ablation technique on the incidence of silent cerebral embolism: a prospective randomized controlled study](https://doi.org/10.1186/s12916-023-03180-3)

**Authors:** Wei-Jie Chen, Chun-Xia Gan, Yang-Wei Cai, Yang-Yang Liu, et al.

**Journal:** BMC Medicine, 2023

**Why it matters:** Even when catheter ablation successfully restores heart rhythm, microscopic clots can silently lodge in the brain — and this trial tests whether a next-generation cooling catheter actually reduces that hidden risk.

---

**Summary**

Catheter ablation for atrial fibrillation (AF) — where radiofrequency energy is used to scar the tissue driving abnormal electrical signals — is highly effective, but the heat applied to actively circulating blood can generate micro-emboli (tiny clots and gaseous particles) that travel to the brain. These "silent cerebral embolisms" (SCEs) produce no immediate symptoms yet show up as new lesions on sensitive imaging in a substantial fraction of patients. This trial asked whether a high-power short-duration (HPSD) strategy, delivering 50 W through a Smart Touch Surround Flow (STSF) catheter — which features 56 circumferential irrigation holes designed to aggressively cool the electrode-tissue interface — reduces SCE incidence compared to the conventional 30–35 W approach using a standard Smart Touch (ST) catheter.

One hundred AF patients were randomized 1:1. High-resolution diffusion-weighted MRI (1 mm slice thickness on a 3.0 T scanner) was performed before and 24–72 hours after ablation to detect new lesions, with cognitive function assessed by the Montreal Cognitive Assessment (MoCA) at baseline, immediately post-procedure, and at three months. The HPSD technique was procedurally faster and required less irrigation fluid, confirming it delivered on its engineering promise. However, SCE rates were nearly identical: 44% in the HPSD group versus 40% in the conventional group (p = 0.685), with no significant differences in lesion count, maximum diameter, or total lesion volume.

Multivariable regression identified persistent AF and a high CHA₂DS₂-VASc score (a validated stroke-risk metric) as the only independent predictors of SCE — not the catheter type or ablation duration. The finding suggests that sluggish, turbulent blood flow in a structurally remodeled, dilated left atrium overwhelms any cooling advantage the hardware provides. Reassuringly, patients who developed SCEs showed no detectable cognitive decline at three months compared to those with clean scans. A key limitation is the relatively small sample of 100 patients, which may have been underpowered to detect modest differences.

---

**Three takeaways**

1. The HPSD/STSF approach produced SCEs in 44% of patients versus 40% with conventional ablation — a difference that was not statistically significant (p = 0.685), meaning the advanced cooling catheter conferred no measurable brain protection.

2. Multivariable regression showed that persistent AF and CHA₂DS₂-VASc score — markers of adverse cardiac remodeling and baseline thrombotic risk — were the only independent predictors of SCE, with catheter type and ablation duration eliminated as predictors.

3. Despite 106 new lesions detected across 42 patients (92% in the telencephalon), MoCA scores were stable at both the immediate post-procedure and three-month assessments, suggesting micro-lesions of this scale do not translate to detectable short-term cognitive decline.

---

**Read the paper:** [https://doi.org/10.1186/s12916-023-03180-3](https://doi.org/10.1186/s12916-023-03180-3)

**Paper:** [Improving mitochondria and ER stability helps eliminate upper motor neuron degeneration that occurs due to mSOD1 toxicity and TDP‐43 pathology](https://doi.org/10.1002/ctm2.336)

**Authors:** Barış Genç, Mukesh Gautam, Öge Gözütok, Ina Dervishi, Santana Sanchez, et al.

**Journal:** Clinical and Translational Medicine, 2021

**Why it matters:** NU-9 is the first compound shown to halt upper motor neuron degeneration — the cortical neurons whose loss defines ALS, primary lateral sclerosis, and hereditary spastic paraplegia — by physically restoring the structural integrity of mitochondria and the endoplasmic reticulum in living animals.

**Summary**

Upper motor neurons (UMNs), the cortical cells that issue commands for voluntary movement, degenerate in ALS, primary lateral sclerosis (PLS), and hereditary spastic paraplegia (HSP), yet have been largely overlooked in drug development because they are difficult to isolate and monitor in vivo. To address this, the researchers crossed disease mouse models — one driven by misfolded SOD1 protein (mSOD1) toxicity, another by TDP-43 pathology — with a UCHL1-eGFP reporter line that labels UMNs with green fluorescent protein, enabling direct visualization and quantification of these specific neurons during treatment. Electron microscopy revealed that both genetic triggers, despite operating through distinct molecular pathways, converge on the same organelle-level destruction: mitochondria lose their cristae (the inner membrane folds essential for energy production), the endoplasmic reticulum (ER) cisternae fracture and detach from ribosomes, and the apical dendrite — the neuron's primary signal-receiving antenna — becomes riddled with vacuoles. Critically, this pattern of damage was also observed in postmortem tissue from human ALS patients, validating the mouse model at the ultrastructural level.

The compound NU-9, identified from a screen of over 50,000 candidates, was administered orally once daily from postnatal day 60 to day 120 in both disease models. At 100 mg/kg/day, NU-9 demonstrated 94% oral bioavailability, robust blood-brain barrier penetration, and no cardiac or systemic toxicity at therapeutic doses. Electron microscopy at end stage showed near-complete restoration of mitochondrial cristae (healthy mitochondria rising from 10% to 86% of the total pool), reassembly of intact ER cisternae with attached ribosomes, and clearance of apical dendrite vacuoles. UMN counts in treated disease mice matched those of healthy wild-type controls, and treated mice performed significantly better on the hanging wire test. One important caveat: NU-9 had no protective effect on lower motor neurons in the spinal cord, which continued to degenerate at the same rate as in untreated controls — underscoring that upper and lower motor neurons have fundamentally different cellular vulnerabilities.

**Three takeaways**

1. Mitochondrial cristae loss and ER fragmentation are convergent structural pathologies in UMNs regardless of whether the upstream trigger is mSOD1 toxicity or TDP-43 pathology, and the same damage pattern is seen in postmortem human ALS tissue.

2. NU-9 treatment at 100 mg/kg/day restored the proportion of structurally healthy mitochondria from ~10% to ~86%, fully reassembled ER cisternae, and cleared apical dendrite vacuoles — returning UMN architecture to wild-type baseline in vivo.

3. NU-9 preserved UMN populations at healthy control levels and improved motor behavior on the hanging wire test, but provided no protection to lower motor neurons, demonstrating that the two neuron populations have distinct survival requirements within the same motor circuit.

**Read the paper:** https://doi.org/10.1002/ctm2.336

**Paper:** [A trophoblast glycoprotein specific 5T4-Vδ2 bispecific T cell engager recruits Vγ9Vδ2-T cells for tumor-selective cytotoxicity across solid malignancies](https://doi.org/10.1016/j.clim.2026.110707)

**Authors:** Milon de Jong, Rok Žiberna, Myrthe Veth, Elisabetta Michielon, et al.

**Journal:** Clinical Immunology, 2026

**Why it matters:** Solid tumors have largely resisted bispecific T cell engager therapies due to on-target toxicity in healthy tissue, and this study presents a strategy using gamma-delta T cells that may sidestep that problem.

**Summary**

Bispecific T cell engagers (bsTCEs) are antibody-like molecules that physically link a tumor antigen to a T cell receptor, forcing immune cells into proximity with cancer cells. While highly effective in blood cancers, their use in solid tumors has been hampered by "on-target off-tumor" toxicity — damage to healthy tissues that express the same antigen being targeted. This study addresses that problem by focusing on two components: the tumor antigen 5T4 (trophoblast glycoprotein), an oncofetal protein broadly overexpressed across solid malignancies but largely absent from healthy adult tissue, and Vγ9Vδ2-T cells, a subset of gamma-delta T cells known for potent anti-tumor activity and an intrinsic capacity to discriminate between stressed tumor cells and normal tissue.

The researchers developed high-affinity VHHs — single-domain antibody fragments derived from camelid antibodies — specific to 5T4, and linked them to a VHH targeting the Vδ2 T cell receptor to create the 5T4-Vδ2 bsTCE. They validated 5T4 expression across a broad panel of solid tumor types and then tested the engager in both conventional 2D cell cultures and more clinically representative 3D patient-derived tumor models. In these systems, the bsTCE triggered robust Vγ9Vδ2-T cell activation, proinflammatory cytokine production, and tumor cell lysis. Critically, when the construct was tested against healthy tissues that do express 5T4 at low levels, Vγ9Vδ2-T cell cytotoxicity was not observed — suggesting that the gamma-delta T cell arm of the engager contributes an intrinsic selectivity that conventional alpha-beta T cell engagers lack. One caveat is that these remain preclinical findings, and whether the tumor-preferential activity holds in the more complex immunosuppressive environment of human tumors in vivo will require clinical investigation.

**Three takeaways**

1. The 5T4-Vδ2 bsTCE induced potent Vγ9Vδ2-T cell-mediated killing and cytokine production in both 2D and 3D patient-derived solid tumor models.

2. 5T4 protein was expressed across the majority of solid malignancies evaluated, supporting its utility as a broad-spectrum therapeutic target.

3. Despite low-level 5T4 expression on some healthy tissues, the bsTCE did not trigger Vγ9Vδ2-T cell cytotoxicity against those tissues, demonstrating tumor-preferential activity in preclinical testing.

**Read the paper:** https://doi.org/10.1016/j.clim.2026.110707

I don't have access to the full text or abstract of this paper — the metadata provided includes only bibliographic information with an empty abstract field, and I can't retrieve the paper from its DOI.

To write accurate show notes without inventing results, I'd need at least one of the following:

- The paper's **abstract**

- The **full text** (or key sections: introduction, results, conclusion)

- The **digest entry** with reasoning

Could you paste the abstract or relevant excerpts? Once you do, I can produce the show notes following the template exactly.

I don't have enough information to write accurate show notes for this paper. The metadata provided only includes a title ("Resurrecting 5T4 drugs with metabolic sensing") and no additional details — no authors, journal, DOI, abstract, full text, or digest entry.

To write show notes that meet the constraints (no invented results, findings grounded in the results section), I would need at minimum:

- **The abstract** (to identify the research question, approach, and headline results)

- **Authors and journal/DOI** (for proper citation)

- Ideally: the full text or digest entry

Could you provide the paper's abstract, DOI, or full text? Once you share those, I can write the show notes accurately and in full.